Effects of Triple Effective RNA (teRNA) on the Inhibition of Hepatocellular Carcinoma Cells

Abstract

The occurrence and development of hepatocellular carcinoma (HCC) is a complicate process involved in genetic mutation and epigenetic regulation. Successful HCC therapy needs multi-targets be involved. The aim of this study was to provide a triple effective RNA (teRNA) which composed of the specific siRNAs targeting NET-1 and VEGF and dsRNA activating TLR3, and explored its anti-HCC roles and mechanism. Real-time quantitative PCR (RT-qPCR), Western blot, immunofluorescence staining, MTT, Annexin V-FITC flow cytometry, Transwell and in-vitro Angiogenesis assay were used to measure the cell biological functions and protein expression analysis. Furthermore in in-vivo mouse model, teRNA inhibited tumor growth were detected by immunohistochemistry and TUNEL assay. Results showed that the proliferation, migration and angiogenesis of HCC cells were inhibited by teRNA effectively, the cell apoptosis also was induced, and further tumor growth was suppressed in-vivo. The gene silencing mechanism of teRNA was in an Ago2-dependent manner with no interferon response. The study suggests that NET-1, VEGF and TLR3 might be better targets for HCC treatment and combined these targets in form of a multi-target small RNA, teRNA could be a stagey for the development of anti-HCC drugs.

hsa_circ_0001955 Promotes Colorectal Cancer Progression by Regulating miR-583/FGF21 Axis

“…For the xenograft tumor model, 4-week-old BALB/c nude mice were purchased from Charles River (Beijing, China) and randomly divided into 3 groups ( n =5, each), including NC, Over-circRNA, and sh-CircRNA groups. 5 × 10 6 HCT116 cells were inoculated subcutaneously into nude mice and the tumor volumes were measured once every 7 days by digital calipers using V = D × d 2 /2 ( D = long axis of the tumor and d = short axis of the tumor) [ 15 ] for a total of 28 days. After 4 weeks, the mice were sacrificed, and the weights of the tumors were measured.…”